Ariya Bio

BREAKING NEWS The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

🙏 Big thanks to @KevinADavies and @GENbio

#CRISPR #globinopathy therapies target fetal globin. But delta globin is closer to adult globin *and* is expressed at low levels throughout life. @ETH_Entprenship Fellow Mandy Boontanrart developed #geneediting "fix" for delta promoter! Finally out @eLife elifesciences.org/articles/85258

I’m so excited to see Mandy Boontanrart and the Ariya Bio team push forward their new approach to tackle #globinopathy!

Blutarmut gehört weltweit zu den häufigsten Erbkrankheiten. Die ETH-Forscherin Mandy Boontanrart hat nun einen vielversprechenden Ansatz für deren Behandlung entdeckt. 🧬✂️ #CRISPRCas #Genschere #Blutarmut @Innosuisse @snf_ch Erfahren Sie mehr:👇 fal.cn/3AogG

.@ETHFoundation1 Spotlight "Hoping to heal" on ETH Pioneer Fellow Mandy Boontanrart and her company Ariya Bio. Her basic research in the @jcornlab (@ETH_DBIOL, @ETH_en) was part of the Phase 2 project portfolio of the NCCR. bit.ly/3NIRjXF #haemoglobinopathies #CRISPR

Congratulations to our 7 new @ETHZurich Pioneer Fellows Paul Baade, Dominic Jud & Burak Cizmeci, Mandy Boontanrart, Karl-Philipp Schlichting, Sonia Meller & Hélène Iven with 5 thrilling projects. See what they do ethz.ch/pioneerfellows… Groundbreaking technology for the industry

Delta Force: Scientists Promote Novel Globin Genetic Therapy for Sickle Cell Disease -- my interview for @GENbio with Mandy Boontanrart @ETH_en on her clever strategy to switch up delta globin to treat #sicklecelldisease #CRISPR, just published @eLife genengnews.com/topics/genome-…

Anaemia is one of the most common hereditary diseases worldwide. ETH researcher Mandy Boontanrart has developed now a promising approach for its treatment. 🧬✂️ #CRISPRCas #GeneScissors #BloodPoverty @snf_ch @Innosuisse Learn more: 👇 fal.cn/3AogC